Is It a Medical Device? Borderline Product Classification for Hand Sanitizer, Mouthwash, Personal Lubricants & Data Recorders Across FDA, EU MDR, Brazil ANVISA and Mexico COFEPRIS

The Classification Question That Trips Up Even Experienced RA Teams

Not every product that touches the human body is a medical device — and not every product that looks like a consumer good escapes medical device regulation. The borderline between medical devices, drugs, cosmetics, biocidal products, and general consumer products is one of the most consequential regulatory determinations your company will make. Get it wrong and you face one of two outcomes: costly over-compliance (wasting months and tens of thousands of dollars on an unnecessary 510(k) or CE marking process), or enforcement action for marketing an unregistered device.

This guide walks through classification logic for four specific product categories that routinely generate borderline questions: hand sanitizers, mouthwash, personal lubricants, and pure data recorders. For each, we analyze the regulatory status across four jurisdictions — United States (FDA), European Union (EU MDR), Brazil (ANVISA), and Mexico (COFEPRIS) — using the latest 2025-2026 regulatory guidance.

Why Borderline Classification Matters More in 2026

Several regulatory developments make borderline classification especially urgent this year:

EU MDR Annex XVI enforcement is maturing. Products without an intended medical purpose — including aesthetic devices, dermal fillers, and certain contact devices — have been regulated under MDR since June 22, 2023, per Implementing Regulation (EU) 2022/2346. The MDCG Manual on Borderline and Classification, Version 4 (September 2025), added new case examples that sharpen the distinction between medical devices and products falling under cosmetics, biocidal, pharmaceutical, or food legislation. If your product sits at the boundary, the latest MDCG guidance directly affects your conformity assessment route.

FDA's 2026 General Wellness Guidance expanded the non-device zone. On January 6, 2026, FDA issued an updated "General Wellness: Policy for Low Risk Devices" guidance, superseding the 2019 version. The new guidance explicitly allows certain sensor-based devices that measure physiological parameters (blood glucose, oxygen saturation, blood pressure, heart rate variability) to qualify as general wellness products — not medical devices — when outputs are intended solely for wellness use and meet specific guardrails. This is a significant expansion of the non-device category for digital health products.

Brazil's ANVISA overhauled its sanitizing product and cosmetic regulations. RDC 989/2025 and IN 394/2025 (published August 20, 2025) replaced the outdated RDC 59/2010 for sanitizing products, introducing a refined two-tier risk classification system aligned with Mercosur standards. RDC 907/2024 updated cosmetic product classification, and RDC 751/2022 (effective March 2023) modernized medical device classification rules to align with EU MDR principles.

Mexico's COFEPRIS issued new classification Q&A and pathway reforms. COFEPRIS published a Q&A in 2025 clarifying which products fall under medical device, pharmaceutical, or cosmetic regulation — including specific guidance on toothpaste and mouthwash claims. The Abbreviated Regulatory Pathway (effective September 2025) and the elimination of certain equivalence pathways changed the registration landscape.

---

Product 1: Hand Sanitizer

Hand sanitizer is one of the most frequently misclassified products. Its classification depends almost entirely on the jurisdiction and the claims made on the label.

United States (FDA)

Classification: OTC Drug (not a medical device)

The FDA classifies hand sanitizers as over-the-counter (OTC) drug products, specifically "consumer antiseptic rub" products under the OTC monograph system. The FDA states directly: "Hand sanitizers are regulated as over-the-counter (OTC, or nonprescription) drugs by the U.S. Food and Drug Administration."

Regulatory basis: 21 CFR Part 333 (Topical Antimicrobial Drug Products). Hand sanitizers fall under the Consumer Antiseptic Rub Products monograph.

Key requirements:

• Active ingredients must comply with the monograph: ethyl alcohol (ethanol) at 60-95%, or isopropyl alcohol (IPA) at 70-91.3%, or benzalkonium chloride (under review)
• Drug establishment registration (required for manufacturers and brand owners, not importers-only)
• National Drug Code (NDC) labeler code and drug listing
• Drug Facts labeling per 21 CFR §201.66
• Drug Good Manufacturing Practices (cGMP per 21 CFR Parts 210/211)
• Methanol and certain other contaminants are prohibited

Not a medical device. Hand sanitizers are not classified under any product code in 21 CFR Parts 800-1299. They do not meet the device definition in Section 201(h) of the FD&C Act because their primary mode of action is chemical (antimicrobial), and their intended use is disease prevention through chemical action on pathogens.

Not a cosmetic. While hand sanitizers may have incidental cosmetic properties, FDA regulates them as drugs due to their antimicrobial claims.

European Union (EU)

Classification: Biocidal Product under Regulation (EU) No 528/2012 (BPR), not a medical device

In the EU, hand sanitizers are classified as biocidal products — specifically Product Type 1 (human hygiene) under the Biocidal Products Regulation (EU) No 528/2012. They are not medical devices and are not subject to MDR requirements.

Key points:

• Ethanol-based hand sanitizers are placed on the EU market under transitional national legislation while ethanol remains under review as an active substance in the BPR review program
• EU-wide product authorization under BPR is not required during this transitional period
• Each Member State may have its own specific national requirements for hand sanitizer formulation, labeling, and notification
• Products making medicinal claims (e.g., "prevents infection with a specific pathogen") could be reclassified as medicinal products under Directive 2001/83/EC

Borderline with medical devices. Per MDCG Manual on Borderline and Classification v4 (September 2025), Section 1.1.3 addresses the borderline between medical devices and biocidal products. Hand sanitizers for general consumer use do not meet the medical device definition in MDR Article 2(1) because they do not have a specific medical purpose and their principal action is not achieved by physical means.

Brazil (ANVISA)

Classification: Sanitizing Product (not a medical device)

In Brazil, hand sanitizers (álcool gel / antisséptico para mãos) are regulated as sanitizing products (produtos saneantes) by ANVISA, not as medical devices or cosmetics.

Regulatory basis: RDC 989/2025 and IN 394/2025 (effective August 20, 2025, replacing RDC 59/2010).

Risk classification:

• Risk Category 1 (notification only) or Risk Category 2 (mandatory registration), depending on formulation toxicity (LD50)
• Hand sanitizers with higher alcohol concentrations typically fall into Risk Category 1, requiring notification rather than full registration

Key requirements:

• Company must hold AFE (Autorização de Funcionamento de Empresa)
• Notification or registration via ANVISA's digital portal
• GMP certification is not required for sanitizing products, but manufacturers must follow appropriate quality standards
• Registration/notification valid for 10 years, renewable
• Imports processed through PAFCO (ANVISA's specialized health surveillance post for cosmetics, sanitizing products, and related categories)

Mexico (COFEPRIS)

Classification: Varies — cosmetic or pharmaceutical, depending on claims

In Mexico, hand sanitizer classification depends on the claims and formulation. COFEPRIS distinguishes between:

• Cosmetic products: If the product makes only general cleansing claims with no antimicrobial claims (e.g., "hand gel for cleansing"), it may be classified as a cosmetic
• Pharmaceutical/OTC products: If the product makes antimicrobial or antiseptic claims (e.g., "kills 99.9% of germs"), it is classified as an OTC pharmaceutical product (medicamento de libre acceso)

Key point from COFEPRIS Q&A (2025): Products with claims related to "bacteria/microorganism control" are understood as pharmaceutical and cannot be registered as cosmetics. This directly applies to hand sanitizers making germ-killing claims.

Import tariffs: As of January 1, 2026, new import tariffs apply to cosmetics imported from countries without free trade agreements with Mexico — 25% for cosmetics (except lipsticks at 36%).

Hand Sanitizer Classification Summary Table

Jurisdiction	Classification	Governing Regulation	Pathway
US FDA	OTC Drug	21 CFR Part 333 (OTC Monograph)	Drug listing + NDC + cGMP
EU	Biocidal Product	Regulation (EU) 528/2012 (BPR)	National transitional authorization
Brazil ANVISA	Sanitizing Product	RDC 989/2025, IN 394/2025	Notification (Risk 1) or Registration (Risk 2)
Mexico COFEPRIS	OTC Drug (if antimicrobial claims) or Cosmetic (if cleansing-only)	General Health Law, COFEPRIS Q&A 2025	Sanitary registration as pharma or cosmetic notification

---

Product 2: Mouthwash

Mouthwash is a classic borderline product because it can fall into medical device, drug, or cosmetic categories depending on its ingredients, mechanism of action, and claims.

United States (FDA)

Classification varies: Medical device, OTC drug, or cosmetic — depending on the product

The FDA recognizes multiple regulatory pathways for mouthwash products:

1. Medical device (Class II) — 510(k) required. If the mouthwash is an antibacterial oral rinse that works by physical means to reduce dental plaque adhesion, it may be classified as a medical device. The FDA product classification database lists "rinse, oral, antibacterial (by physical means)" under regulation 21 CFR 872.3225 (Oral rinse to reduce the adhesion of dental plaque), classified as Class II with product code EIC. Special controls include the Class II Special Controls Document for Oral Rinse to Reduce the Adhesion of Dental Plaque. These devices are eligible for 510(k) Third Party Review.

2. OTC drug. If the mouthwash contains active ingredients intended to prevent or reduce gingivitis, plaque, or caries by chemical means (e.g., chlorhexidine, cetylpyridinium chloride, fluoride), it is regulated as an OTC drug under the relevant OTC monograph provisions (21 CFR Part 355 for fluoride products, 21 CFR Part 356 for antimicrobial products).

3. Cosmetic. If the mouthwash makes only cosmetic claims (e.g., "freshens breath," "provides a clean feeling") and does not contain active drug ingredients or make therapeutic claims, it is regulated as a cosmetic with no premarket approval required.

Decision tree for US mouthwash classification:

• Does the product claim to treat or prevent disease (gingivitis, caries, periodontal disease)? → Drug (OTC or prescription)
• Does the product reduce plaque adhesion by physical (non-chemical) means? → Medical device (Class II, 510(k) required)
• Does the product only freshen breath with no therapeutic claims? → Cosmetic

European Union (EU)

Classification: Cosmetic, medical device, or biocidal product — depending on claims and mechanism

Under EU law, mouthwash classification depends on claims and mechanism of action:

1. Cosmetic product (most common). Most consumer mouthwashes are classified as cosmetics under Regulation (EC) No 1223/2009. Claims such as "freshens breath" or "provides a clean feeling" are cosmetic claims. Safety assessment, responsible person appointment, CPNP notification, and PIF (Product Information File) are required.

2. Medical device. If the mouthwash's principal intended action is achieved by physical means and it has a specific medical purpose (e.g., "treatment of gingivitis"), it could potentially be qualified as a Class IIa medical device under MDR Annex VIII Rule 5 (invasive device with respect to body orifices). However, the MDCG Manual on Borderline v4 notes that products whose action is primarily chemical are not medical devices.

3. Biocidal product. If the mouthwash makes antimicrobial claims (e.g., "kills oral bacteria") without a specific medical purpose, it could fall under the Biocidal Products Regulation (EU) No 528/2012, Product Type 1 (human hygiene).

Key guidance: The MDCG Manual on Borderline v4 (September 2025), Section 1.1.5, discusses dental product borderline issues. MDCG 2022-5 (Guidance on borderline between medical devices and medicinal products) clarifies that if the principal intended action is pharmacological, immunological, or metabolic, the product is a medicinal product, not a device.

Brazil (ANVISA)

Classification: Cosmetic (Grade 1 or Grade 2), or medical device — depending on claims and formulation

Under ANVISA's regulatory framework:

1. Cosmetic (most common). Mouthwash is typically classified as a personal hygiene product (cosmetic) under RDC 907/2024 and classified as Grade 1 (low risk) or Grade 2 (higher risk, requiring registration). Most standard mouthwashes fall into Grade 1 (notification only).

2. Medical device. If the mouthwash claims to treat gingivitis or periodontal disease by physical means and meets the medical device definition under RDC 751/2022, it could be classified as a medical device. This is rare in practice.

Mexico (COFEPRIS)

Classification: Cosmetic or pharmaceutical — depends entirely on claims

The COFEPRIS Q&A (2025) provides specific guidance for toothpaste and mouthwash:

• Cosmetic: Mouthwash is classified as a cosmetic if it complies with the limits for ingredients in the Cosmetic Ingredients Listing and makes no claim that can be understood as medical or pharmaceutical
• Pharmaceutical: Claims such as "whitening," "plaque removing/preventing," "calcifying," "preventing/reducing cavities," or "bacteria/microorganism control" are all understood as pharmaceutical. A mouthwash making any of these claims cannot be registered as a cosmetic

This is a strict standard. Many products that would be marketed as OTC drugs in the US may need pharmaceutical registration in Mexico.

Mouthwash Classification Summary Table

Jurisdiction	Classification	Governing Regulation	Key Differentiator
US FDA	Device (Class II), OTC drug, or Cosmetic	21 CFR 872.3225 / Part 355 / Part 356 / FD&C Act	Physical vs chemical action; therapeutic vs cosmetic claims
EU	Cosmetic, Device, or Biocidal	(EC) 1223/2009 / MDR / BPR	Claims + mechanism of action (physical vs chemical)
Brazil ANVISA	Cosmetic (Grade 1/2) or Device	RDC 907/2024 / RDC 751/2022	Claims and risk level
Mexico COFEPRIS	Cosmetic or Pharmaceutical	General Health Law, COFEPRIS Q&A 2025	Any therapeutic claim = pharmaceutical

---

Product 3: Personal Lubricants

Personal lubricants are one of the most frequently asked-about borderline products because their classification varies significantly across jurisdictions.

United States (FDA)

Classification: Class II Medical Device — 510(k) required

The FDA classifies personal lubricants as Class II medical devices under regulation 21 CFR 884.5300 (Condom), with product code NUC (lubricant, personal).

FDA definition (from the Product Classification Database): "A personal lubricant, for penile and/or vaginal application, intended to moisturize and lubricate, to enhance the ease and comfort of intimate sexual activity, and supplement the body's natural lubrication. This product may or may not be compatible with natural rubber latex, polyisoprene, and/or polyurethane condoms."

Regulatory requirements:

• 510(k) premarket notification required (not exempt)
• Substantial equivalence must be demonstrated to a legally marketed predicate device
• Biocompatibility testing, condom compatibility testing (ASTM D7661-18), and safety data required
• Drug GMP (cGMP) applies to the extent relevant; with QMSR effective February 2, 2026, ISO 13485:2016 is incorporated by reference into 21 CFR Part 820
• Facility registration and device listing required
• Eligible for 510(k) Third Party Review

Product code variants:

• NUC — standard personal lubricant (Class II, 21 CFR 884.5300)
• A separate classification exists for "lubricant, personal, gamete, fertilization, and embryo compatible" — also Class II, for lubricants specifically intended to support fertility procedures

Recent 510(k) examples: K241443 (Sutil Luxe Personal Lubricant, Hathor Professional Skincare), K210972 (H2O Warming Personal Lubricant, CC Wellness). Both cleared under regulation 884.5300, product code NUC.

Not a cosmetic. FDA's position is clear: personal lubricants are medical devices, and cosmetic registration does not permit their sale. Companies attempting to market personal lubricants under cosmetic registration alone face enforcement action including product recalls and fines.

European Union (EU)

Classification: Medical device (Class IIb or IIa) or Annex XVI product — depending on intended purpose

Under the EU MDR, personal lubricants can be classified in different ways:

1. Medical device — if therapeutic claims are made. If the lubricant claims to treat vaginal dryness associated with a medical condition (e.g., atrophic vaginitis, dyspareunia), or is intended for use during fertility procedures, it qualifies as a medical device. Classification under MDR Annex VIII:

• Rule 5 (invasive device with respect to body orifices): If the device is intended for short-term use in the vaginal canal and is not surgically invasive, it would typically be Class IIa (transient use) or Class IIb (long-term use)
• Rule 14 (devices incorporating substances): If the lubricant incorporates a substance (e.g., a pharmacologically active ingredient) that may assist the device's function, the higher classification applies. Per Rule 14, such devices are Class IIb if the substance is ancillary, or Class III if the substance is the primary mode of action
• Rule 21 (devices introduced into the body via body orifices): Introduces additional classification considerations for substances absorbed by mucous membranes

2. Annex XVI product — if no medical purpose claimed. Personal lubricants with only non-medical claims (e.g., "enhances comfort during intimate activity") could potentially be assessed under MDR Article 1(2) and Annex XVI. However, personal lubricants are not explicitly listed in any of the six groups in Annex XVI. Annex XVI covers contact lenses, subdermal implants, dermal fillers, liposuction equipment, electromagnetic radiation equipment, and brain stimulation equipment — not topical lubricants.

Practical outcome: Most personal lubricants sold in the EU with medical or therapeutic claims are regulated as Class IIa or IIb medical devices under Rule 5. Products with no medical claims at all may fall outside MDR scope entirely, potentially being classified as consumer products or cosmetics depending on the Member State.

MDCG 2023-5 (Guidance on qualification and classification of Annex XVI products) and MDCG 2022-5 (Guidance on borderline between medical devices and medicinal products) provide the interpretive framework for these determinations.

Brazil (ANVISA)

Classification: Personal hygiene product (cosmetic) or medical device — depending on claims

Under ANVISA's framework:

1. Personal hygiene product (cosmetic) — most common. Most personal lubricants sold in Brazil are classified as personal hygiene products under RDC 907/2024. They are registered as Grade 1 or Grade 2 cosmetics depending on formulation and risk profile. Standard water-based lubricants typically fall into Grade 1 (notification only).

2. Medical device. If the lubricant makes specific therapeutic claims (e.g., "treats vaginal dryness caused by menopause"), it could be classified as a medical device under RDC 751/2022. The classification would follow rules analogous to EU MDR (invasive device via body orifice).

Key difference from US: Brazil's default classification for personal lubricants is cosmetic/personal hygiene, not medical device. This is the opposite of the US approach. Manufacturers entering both markets must prepare completely different regulatory dossiers.

Mexico (COFEPRIS)

Classification: Medical device or cosmetic — depends on claims and intended use

COFEPRIS classifies products based on their intended purpose:

1. Medical device. If the lubricant makes claims related to treatment of a medical condition (e.g., vaginal dryness treatment, use during medical procedures, fertility assistance), COFEPRIS is likely to classify it as a medical device. Classification would follow the risk-based system: Class I (low risk), Class II (moderate risk), or Class III (high risk) depending on the claims and intended duration of use.

2. Cosmetic. If the lubricant makes only non-therapeutic claims (e.g., "enhances comfort"), it may be classified as a cosmetic product under COFEPRIS cosmetic regulations.

Practical note: COFEPRIS's strict interpretation of claims (as documented in the 2025 Q&A) means that any claim that "can be understood as medical or pharmaceutical" pushes the product into pharmaceutical or medical device territory.

Personal Lubricant Classification Summary Table

Jurisdiction	Classification	Governing Regulation	Key Requirement
US FDA	Medical Device (Class II)	21 CFR 884.5300, Product Code NUC	510(k) required
EU	Medical Device (Class IIa/IIb) or non-MDR	MDR Annex VIII Rules 5/14	CE marking + NB assessment if medical device
Brazil ANVISA	Cosmetic/personal hygiene (Grade 1/2) or Device	RDC 907/2024 / RDC 751/2022	Notification or registration as cosmetic (most common)
Mexico COFEPRIS	Medical Device or Cosmetic	General Health Law, COFEPRIS Q&A 2025	Sanitary registration; claims determine category

---

Product 4: Pure Data Recorders

The question here is specific: hardware or software that only collects, stores, or transmits physiological data — without any intended diagnostic interpretation — is it a medical device?

United States (FDA)

Classification: Generally not a medical device (MDDS / General Wellness), with important exceptions

FDA's framework for pure data recorders has evolved significantly:

1. Medical Device Data Systems (MDDS) — reclassified to Class I (exempt from 510(k)). Under Section 520(o)(1)(D) of the FD&C Act, software functions that solely transfer, store, convert formats, or display medical device data without modifying the data or controlling a connected medical device are excluded from the device definition entirely. FDA's MDDS guidance (originally 2015, still applicable) clarified that:

• Software that only stores data from a pulse oximeter for later retrieval by a physician → not a regulated device
• Software that only transmits ECG data from a monitor to an EMR system → not a regulated device
• Hardware modems explicitly promoted as part of an MDDS system → may fall within scope
• Software that converts data from HL7 to FHIR format according to preset specifications → not a regulated device

2. General Wellness products — 2026 Guidance expansion. FDA's January 6, 2026 update to "General Wellness: Policy for Low Risk Devices" significantly expanded the non-device category for products that measure physiological parameters:

A product can qualify as a general wellness product (not a regulated medical device) if:

• It is non-invasive and not implanted
• It is not intended for disease diagnosis, treatment, or clinical management
• It does not prompt or guide specific clinical action
• Outputs are intended solely for wellness use (e.g., tracking trends for lifestyle purposes)
• It does not mimic clinical-grade values unless appropriately validated
• It is not intended as a substitute for an FDA-authorized device

Product code PWC (general wellness product) was created in FDA's Product Classification Database for import purposes.

3. When IS a data recorder a medical device? If the product:

• Alarms or triggers clinical alerts based on data thresholds (e.g., "alerting when heart rate exceeds 150 BPM") → Medical device
• Uses algorithms to interpret the data for diagnostic purposes → SaMD, likely Class II
• Is intended for active patient monitoring in a clinical setting → Medical device (21 CFR 880.6310 or other applicable classification)

European Union (EU)

Classification: Depends on whether the software provides information used for medical purposes

Under EU MDR, the classification of data recorders hinges on whether the software "provides information which is used to take decisions with diagnosis or therapeutic purposes" (MDR Annex VIII Rule 11).

1. Not a medical device. Software that only stores, transmits, or displays raw data without interpretation and is not intended for medical decision-making is not a medical device. The MDCG Manual on Borderline v4 confirms this approach.

2. Class I medical device. Software that collects and displays physiological data for monitoring purposes (without providing diagnostic interpretation) could be Class I if it is non-invasive and intended for transient use. However, under Rule 11 (software), many monitoring functions result in Class IIa classification.

3. Class IIa or higher. If the software:

• Provides information used to take decisions for diagnostic or therapeutic purposes → Rule 11 → Class IIa (minimum)
• Monitors physiological parameters where variations could result in immediate danger → Rule 11 → Class IIb or III
• Uses algorithms to transform data into diagnostic information → SaMD, Class IIa or higher

Key distinction: The EU applies Rule 11 (software classification) more aggressively than the FDA's MDDS exclusion. A product that qualifies as non-device in the US could be Class IIa in the EU.

Brazil (ANVISA)

Classification: Follows EU MDR-aligned rules under RDC 751/2022

Brazil's medical device classification under RDC 751/2022 (effective March 2023) aligns closely with EU MDR, including specific rules for software as a medical device:

• Pure data storage/transmission without medical purpose: not a medical device
• Software that provides information used for diagnostic or treatment decisions: medical device, Class II or higher (Brazilian Class II = EU IIa)
• Software for monitoring physiological parameters: medical device, classification depends on risk

ANVISA has published specific guidance on software classification, and the rules mirror EU MDR's approach. The practical implication: a data recorder that is non-device in the US may require ANVISA notification (Class I/II) or registration (Class III/IV) in Brazil.

Mexico (COFEPRIS)

Classification: Medical device or non-regulated — depends on claims

Under COFEPRIS's risk-based framework:

• Not a medical device: Hardware or software that only stores, transmits, or displays data without medical claims and without clinical interpretation. This is consistent with Mexico's alignment with GHTF/IMDRF principles
• Medical device (Class I or II): If the data recorder is marketed for medical monitoring purposes or is intended for use with other medical devices in a clinical workflow. Classification would follow COFEPRIS's standard three-tier system
• SaMD updates: NOM 241-SSA1-2025 and Mexican Pharmacopoeia updates for 2025-2026 include evolving requirements for software as a medical device

Pure Data Recorder Classification Summary Table

Jurisdiction	Classification	Key Regulation	Threshold for Device Status
US FDA	Non-device (MDDS exclusion or General Wellness) or Device (Class I-III)	FD&C Act §520(o)(1)(D); 2026 General Wellness Guidance	Adds clinical interpretation, alerts, or active monitoring → device
EU	Non-device, Class I, or Class IIa+	MDR Annex VIII Rule 11	Provides info for medical decisions → device (Class IIa minimum)
Brazil ANVISA	Non-device or Class II+	RDC 751/2022	Software for monitoring/diagnostic decisions → device
Mexico COFEPRIS	Non-device or Class I/II	General Health Law, NOM 241-SSA1-2025	Medical monitoring claims → device

---

Cross-Jurisdiction Decision Framework

For any borderline product, apply this four-step analysis across each jurisdiction independently. Do not assume that classification in one jurisdiction predicts classification in another.

Step 1: Determine the Intended Purpose

What does the manufacturer claim the product does? Claims on labels, marketing materials, websites, and instructions for use are all relevant. This is the single most important factor.

Step 2: Identify the Mechanism of Action

• Physical/mechanical → Tends toward medical device classification (FDA, EU MDR)
• Chemical/pharmacological → Tends toward drug/pharmaceutical classification
• Metabolic/immunological → Always drug/biologic, never device
• Information/data only → Tends toward non-device or Class I

Step 3: Check Each Jurisdiction's Specific Rules

Question	US FDA	EU MDR	Brazil ANVISA	Mexico COFEPRIS
Are therapeutic/disease claims made?	Drug (OTC or Rx)	Medicinal product or device	Drug or device	Pharmaceutical or device
Is the action physical/mechanical?	Medical device	Medical device	Medical device	Medical device
Is the action chemical?	Drug (usually)	Medicinal product or biocidal	Cosmetic or drug	Cosmetic or pharmaceutical
Are only cosmetic claims made?	Cosmetic (no premarket)	Cosmetic (EC 1223/2009)	Cosmetic (Grade 1/2)	Cosmetic (if no therapeutic claims)
Is the product for general wellness only?	May be non-device	Not specifically addressed	Not specifically addressed	Not specifically addressed

Step 4: Document Your Classification Rationale

Every borderline product should have a written classification rationale that:

1. States the intended purpose and all claims
2. Identifies the mechanism of action
3. Applies the relevant classification rules for each target jurisdiction
4. Cites specific regulation numbers, guidance documents, and product codes
5. Is signed and dated by a qualified regulatory affairs professional

---

Key Reference Documents

Document	Jurisdiction	Relevance
21 CFR Parts 210-211, 330, 333	US FDA	Drug cGMP, OTC monographs
21 CFR 872.3225, 884.5300	US FDA	Oral rinse (device), personal lubricant (device)
FD&C Act §520(o)(1)(D)	US FDA	MDDS exclusion from device definition
General Wellness Guidance (Jan 2026)	US FDA	Expanded non-device category for low-risk wellness products
MDR Article 2(1), Article 1(2)	EU	Medical device definition, scope
MDR Annex VIII (Rules 1-22)	EU	Classification rules for medical devices
MDR Annex XVI	EU	Products without medical purpose
MDCG Manual on Borderline v4 (Sep 2025)	EU	Borderline case examples
MDCG 2022-5	EU	Borderline between devices and medicinal products
MDCG 2023-5	EU	Annex XVI qualification and classification
Implementing Regulation (EU) 2022/2346	EU	Common Specifications for Annex XVI products
Implementing Regulation (EU) 2022/2347	EU	Reclassification of Annex XVI active products
Regulation (EU) 528/2012 (BPR)	EU	Biocidal Products Regulation
Regulation (EC) 1223/2009	EU	Cosmetics Regulation
RDC 751/2022	Brazil	Medical device classification (replaces RDC 185/2001)
RDC 907/2024	Brazil	Cosmetic product classification
RDC 989/2025, IN 394/2025	Brazil	Sanitizing product regulations
RDC 907/2024	Brazil	Cosmetics, personal hygiene products, and perfumes
General Health Law (Article 376)	Mexico	Sanitary registration requirements
COFEPRIS Q&A (2025)	Mexico	Product classification clarifications
NOM 241-SSA1-2025	Mexico	GMP standard for medical devices

---

The Takeaway

Borderline product classification is not a one-and-done exercise. The same product — the same formulation, the same physical hardware — can be an OTC drug in the US, a biocidal product in the EU, a cosmetic in Brazil, and a pharmaceutical in Mexico. The determining factors are jurisdiction-specific definitions, the claims you make, and the mechanism of action you describe.

Before you invest in regulatory submissions for any borderline product:

1. Do not assume US classification applies globally. Personal lubricants are Class II devices in the US but cosmetics in Brazil. Hand sanitizers are OTC drugs in the US but sanitizing products in Brazil and biocidal products in the EU.
2. Audit every claim on every label and marketing asset. A single claim like "kills germs" or "prevents plaque" can shift a product from cosmetic to pharmaceutical or medical device classification.
3. Document your classification rationale per jurisdiction. Regulators expect to see a written analysis, not a verbal argument.
4. Monitor MDCG and COFEPRIS guidance updates. The MDCG Manual on Borderline v4 (September 2025) and COFEPRIS Q&A (2025) both contain new examples that directly affect borderline determinations.

The cost of a wrong classification decision is not just regulatory — it is commercial. Months of delay, wasted dossier preparation, and potential enforcement action can be avoided with a jurisdiction-specific, claim-specific, mechanism-specific analysis done before the first submission.